Business Context and Reporting Period
Company: Alzamend Neuro, Inc. (ALZN)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended April 30, 2025
Business Overview: Alzamend is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer's disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). The company has no commercial revenue and relies on financing to fund operations. Its pipeline consists of two primary candidates: AL001 (a lithium ionic cocrystal) and ALZN002 (a cell-based therapeutic vaccine).
Key Financial Metrics
| Metric | Fiscal Year 2025 | Fiscal Year 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(4,514,853) | $(9,947,746) |
| Net Loss Attributed to Common Shares | $(5,105,084) | $(9,947,746) |
| Operating Expenses | $4,496,824 | $9,937,645 |
| Cash and Cash Equivalents (End of Period) | $3,948,658 | $376,048 |
| Accumulated Deficit | $(58,535,261) | $(54,020,408) |
| Net Cash Used in Operating Activities | $(6,568,186) | $(8,269,993) |
| Net Cash Provided by Financing Activities | $10,440,796 | $3,652,425 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 55% (from $9.9M to $4.5M), driven primarily by a 78% reduction in Research and Development (R&D) expenses ($6.5M to $1.4M) and a 12% reduction in General and Administrative (G&A) expenses.
- Loss Narrowing: Net loss decreased by approximately 55% year-over-year, reflecting the significant reduction in operating costs.
- Liquidity Improvement: Cash balances increased significantly from $376,000 to $3.9 million, primarily due to $10.4 million in net financing proceeds from the issuance of preferred stock and common stock via an At-The-Market (ATM) offering.
- Capital Structure: The company completed multiple equity financings, including Series A, Series B, and Series C convertible preferred stock issuances, and executed three reverse stock splits (1-for-15, 1-for-10, and 1-for-9) during the period to maintain listing compliance.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Clinical Progress
- AL001: Phase IIA clinical trial completed in March 2023 with positive topline data. The company identified a Maximum Tolerated Dose (MTD) of 240 mg TID. In May 2025, the company initiated Phase II imaging trials with Massachusetts General Hospital to assess brain lithium levels. Phase III trials are contingent on successful Phase II results.
- ALZN002: Phase I/IIA clinical trial initiated in April 2023. However, the trial is currently on hold as the Contract Research Organization (CRO), Biorasi, terminated its contract in February 2024. The company is seeking a replacement CRO and does not expect to resume the trial until mid-2026.
Going Concern Warning
The independent auditors have issued a "going concern" opinion, expressing substantial doubt about the company's ability to continue as an ongoing business. Management believes current cash on hand ($3.9M) is insufficient to fund operations for the next 12 months. The company requires substantial additional funding to complete clinical trials and commercialization efforts.
Material Weakness in Internal Controls
The company identified a material weakness in internal control over financial reporting related to insufficient accounting personnel to segregate duties, review manual journal entries, and execute account reconciliations. Remediation efforts are underway but require hiring additional staff.
Risk Factors
- Funding Risk: Failure to raise capital could force the delay or elimination of R&D programs.
- License Obligations: The company must meet operational and financial milestones to maintain licensing rights from the University of South Florida Research Foundation. Failure to do so could result in termination of licenses.
- Regulatory Risk: High failure rate for Alzheimer's drug candidates; no assurance of FDA approval for AL001 or ALZN002.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the "going concern" warning and the explicit statement that current funds are insufficient for 12 months.
- ALZN002 CRO Status: Confirm the engagement of a new CRO for the ALZN002 trial, as the current delay until mid-2026 significantly impacts the development timeline.
- License Milestones: Review the specific financial and operational milestones required by the University of South Florida licenses to ensure the company can meet them without losing exclusivity.
- Internal Control Remediation: Monitor progress on hiring accounting staff to remediate the material weakness in financial reporting controls.
- Dilution Impact: Assess the dilution impact of recent and potential future equity issuances (Series C preferred stock and warrants) on existing shareholders.